Skip to content
EntityQ7838098· pop 8· linked from 376 articles

tremelimumab

Sign in to save

Also known as TICILIMUMAB, CP-675206, CP-675,206

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).

Wikidata facts

Has use
medication
Show 2 more facts
World Health Organisation international non-proprietary name
tremelimumab
subject has role
monoclonal antibody
Sources (2)

via Wikidata · CC0

~4 min read

Encyclopedic overview

11 sections
Contents
  • Medical uses
  • Mechanism of action
  • History
  • Clinical trials
  • Melanoma
  • Mesothelioma
  • Non-small cell lung cancer
  • Society and culture
  • Legal status
  • Names
  • References

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma (a type of liver cancer). Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system (the body’s natural defenses).

The most common side effects when used in combination with durvalumab include rash, pruritus (itching), diarrhea, abdominal (belly) pain, increased levels of liver enzymes, fever, hypothyroidism (an underactive thyroid gland), cough, peripheral edema (swelling especially of the ankles and feet) and increased level of lipase (an enzyme that helps digest fat, mainly made in the pancreas).

Excerpted from Wikipedia’s “tremelimumab” article, available under the CC BY-SA 4.0 licence.

Available in 8 languages

via Wikidata sitelinks · CC0